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“The traditional understanding of the dose response
relationships for irradiated cells was that equal dose
increments cause a constant decrease in cell survival. This
reflects a random process of cell killing. It means, that if
100 lethal hits are distributed randomly throughout 100
equally radiation sensitive cells they will not kill them all, and
on average 37 cells will survive” – over the years, this has
been a dogma and a guideline for clinical radiotherapy
[1].
For any given patient, success or failure in radio-
therapy is an “all or none” phenomenon; if one tumour
clonogenic cell survives all the dose is effectively wasted.
However, for a series of tumours of the same type and
stage, the dose-response is represented by a tumour
control probability curve (TCP) the shape of which may
differ because cell killing is a random process affected
Artyku∏ na zaproszenie  • Invited article
NOWOTWORY Journal of Oncology • 2004 • volume 54
Number 1 • 1–10
From conventional averages to individual dose painting in radiotherapy for
human tumours: challenge to non-uniformity
Bogus∏aw Maciejewski1, H. Rodney Withers2
The exploitation of a number of current clinical trials and reports on outcomes after radiation therapy (i.e. breast, head and
neck, prostate) in clinical practice reflects many limitations for conventional techniques and dose-fractionation schedules and
for “average” conclusions. Even after decades of evolution of radiation therapy we still do not know how to optimize
treatment for the individual patient and only have “averages” and ill-defined “probabilities” to guide treatment prescription.
Wide clinical and biological heterogeneity within the groups of patients recruited into clinical trials with a few-fold variation
in tumour volume within one stage of disease is obvious. Basic radiobiological guidelines concerning average cell killing of
uniformly distributed and equally radiosensitive tumour cells arose from elegant but idealistic in vitro experiments and seem
to be of uncertain validity. Therefore, we are confronted with more dilemmas than dogmas. Nonlinearity and in homogeneity
of human tumour pattern and response to irradiation are discussed. The purpose of this paper is to present and discuss various
aspects of non-uniform tumour cell targeted radiotherapy using conformal and dose intensity modulated techniques.
Od konwencjonalnych uogólnieƒ do indywidualnego „dose painting”
w radioterapii nowotworów u ludzi: wyzwanie dla niejednorodnoÊci
Praktyczne wykorzystanie wyników kontrolowanych badaƒ klinicznych i doniesieƒ dotyczàcych wyników leczenia promieniami
(pierÊ, region g∏owy i szyi, gruczo∏ krokowy) wskazuje na szereg ograniczeƒ w stosowaniu konwencjonalnych technik
i sposobów frakcjonowania dawki promieniowania oraz „Êrednich” i uogólnionych wskazaƒ i wniosków. Pomimo rozwoju
radioterapii w ostatnich dziesi´cioleciach nie wiadomo, jak optymalizowaç t´ metod´ leczenia u indywidualnego pacjenta
i przewodnikiem dla planowania radioterapii nadal pozostajà wskazówki „uÊrednione” i nieprecyzyjnie zdefiniowane
„prawdopodobieƒstwa”. Powszechnie wiadomo, ˝e grupy chorych kwalifikowanych do kontrolowanych badaƒ klinicznych
charakteryzuje du˝a niejednorodnoÊç kliniczna i biologiczna i ˝e w obr´bie jednego stopnia zaawansowania obj´toÊç guzów
nowotworowych mo˝e ró˝niç si´ kilkakrotnie. To czyni wàtpliwà wiarygodnoÊç przes∏anek radiobiologicznych, dotyczàcych
Êrednich wskaêników popromiennej Êmierci jednakowo promienioczu∏ych i równomiernie rozmieszczonych komórek w guzie
nowotworowym. Te przes∏anki wynikajà z eleganckich, ale idealistycznych badaƒ in vitro i majà wàtpliwe prze∏o˝enie
kliniczne. Tak wi´c wspó∏czesny radioterapeuta napotyka na wi´cej dylematów ni˝ dogmatów. W pracy dyskutowana jest
niejednorodnoÊç biologicznej charakterystyki nowotworów u ludzi i ich nieliniowa odpowiedê na promieniowanie.
Przedstawiono ró˝ne aspekty niejednorodnej, komórkowo zogniskowanej radioterapii przy u˝yciu technik konformalnych
i modulacji intensywnoÊci dawki.
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by biological variables. After exposure of a series of
identical (cell sensitivity and density) tumours to a given
dose (single or fractionated) there is a Poisson distribution
of the number of surviving clonogenic cells per tumour. If,
for example, a certain dose reduces the cell survival to an
average of one clonogen per tumour there will be 37% of
tumours sterilized and the remaining 63% not cured, with
one or more surviving cells, although the total number of
surviving clonogens will be the same as the number of
tumours irradiated. Does it work in the clinic and are the
averages useful in daily practice in radiotherapy?
Dogma of “averages” and value of “probabilities”
In oncology, the major interest is focused on improve-
ment of long-term treatment outcome (disease-free and
overall survival) by testing new methods of therapy or
their combinations. Retrospective studies are usually the
source of indirect guidelines for designing randomized
prospective trials. Patient recruitment is almost always
based on TNM stage and tumour site, and on a few
clinical or histopathological predictors, and the results
are presented as crude or actuarial averages.
B r e a s t  c a n c e r
There are only a few topics in oncology that have gene-
rated so much controversy over the years as has post-
mastectomy radiotherapy (RT).
The DBCG 82 trial from Denmark [2] is one of the
most representative and often cited trials. It gathered
3100 postmenopausal high-risk breast cancer patients
after mastectomy. They were randomized either into (arm
A) 8 CMF cycles with post op-RT with 50 Gy in 25
fractions given between the first and the second cycle or
into (arm B) of 9 CMF cycles only. There was a 15%
gain in 10-year disease-free survival (DFS) and 9% in
18-year overall survival (OS), but there was no difference
in the incidence of distant metastasis. Survival benefit
for small tumours and/or 1-3 positive nodes was at least of
the same magnitude as for large tumours.
Metaanalysis of 36 trials including 28500 patients
showed equivalent 10-year survival for more extensive
radical surgery as for breast conserving surgery with
postoperative RT [3]. In the EORTC trial 10001 and
22881-10881 testing efficacy of the boost dose for T1, T2
breast cancers, the average decrease in local recurrence
rate was by 3-6% in favour of 16 Gy boost, with no
difference in local regional control, distant metastases
and overall survival [4, 5].
These few “key” studies on more than 30000 patients
show that, on average, a subgroup of breast cancer
patients could benefit from postmastectomy radiotherapy.
But indications for this method of combined therapy are
still an issue for debate and the question of who may not
benefit from loco-regional irradiation remains open.
Except for breast preservation (cosmetic result is often
controversial) there is no convincing advantage of con-
serving surgery with irradiation over radical mastectomy.
To the question of whether a boost of 16 Gy is on average
beneficial, the answer is that on average it is not. It is
still an unanswered question how to identify a subgroup of
patients with early breast cancer and with very high risk of
distant failure. Therefore, average results lead us to
average conclusions only.
H e a d  a n d  n e c k  c a n c e r s
The main lesson we learned from retrospective studies
supported by clinical trials is that accelerated repopulation
of surviving tumour (epithelial) clonogenic cells reduces
the net cell kill effect of daily irradiation above week 4,
and above week 6 of treatment it may neutralize most or
even all the cell kill effect of daily fractions. The evidence
of that is the existence of an “effect plateau” (Figure 1A),
which means that each extra dose given beyond week 6 of
RT is practically lost (no increase in loco-regional control)
[1, 6]. These findings lead to the idea that by shortening
overall treatment time (OTT) and/or by increase in total
dose (TD) giving two- or three daily fractions one may
expect significant benefit in long-term local tumour
control for locally advanced H & N cancers. Recent
studies suggest that the relationship between tumour
control probability and OTT (TCP-OTT) might be
nonlinear [7]. This means that the benefit from shortening
OTT may not be quite as great as the detriment from
equivalent protraction of OTT.
Careful and precise meta-analysis (MARCH) of 15
well known trials on H & N cancers (13600 patients) gives
an average absolute 6-year survival benefit of 3% and
a 7% benefit for loco-regional control (LRC) for altered
RT [8]. Any subgroup of patients defined according to
the tumour site did not benefit more or less from altered
RT than any other groups. This study shows that the
averages, even being significant, are not promising but
rather discouraging. Interpretation of particular trials is
also confusing [6]. CHART showed no benefit for T1-2
oral cavity, oropharyngeal and hypopharyngeal cancers.
In contrast, the PMH-Toronto trial produced LRC benefit
of 12% for small tumours (especially hypopharynx) but no
gain for larger ones. In the EORTC 22851 trial, 18%
LRC benefit has been noted for advanced and un-
favourable T & N patterns but when consequential and
late complications were accounted for therapeutic gain
dropped down to zero. In RTOG 9003 and in EORTC
22791 trials, hyperfractionation (HF) schedules were
almost the same but LRC benefit was about 3.5 times
higher in the EORTC trial (4.4% vs. 16.2%). Even within
the same institution (MDACC) two trials testing efficacy
of the concomitant boost (72 Gy in 42 fractions) showed
at least a 2 fold difference [6] in the LRC benefit although
in both trials similar tumour sites and stages were
included. One of the earliest trials (RTOG 83-13)
including various tumour sites and stages clearly showed
an “effect plateau” [8]. Increase in total dose from 72 Gy
through 76.8 Gy, to 81.6 did not produce any increase in
the LRC (OTT was also prolonged respectively).
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All these examples are not deliberately selected for
this paper but they are taken from well known and often
cited European and US studies. Wide variations in total
doses (TD), doses per fraction (dx), overall treatment
times (OTT), tumour sizes and sites do not allow
separation of the effect of dose from that of OTT, and to
define which individual tumours may benefit from altered
radiotherapy.
P r o s t a t e  c a n c e r
Large clinical studies on conventional radiotherapy for
locally advanced prostate cancers (LAPC) provide many
controversies [10-14]. Because the LAPC is a very hetero-
genous group of tumours some studies support, whereas
others question a dose-response effect which makes any
conclusion uncertain.
It is impossible to separate importance of clinical
and histological predictors (T stage, PSA, Gleason Score)
from the effect of dose escalation. Lyons et al. [12]
postulate that dose escalation plays an important role for
intermediate risk patients whereas for low- and high risk
patients the PSA and the GS are more important than the
dose. Although a few studies identify radiation dose as an
independent predictor they are mostly retrospective and
include heterogenous groups of patients. Among clinical
trials only one seems to support a dose-effect relationship
[11]. Moreover, interpretation of the results is compli-
cated by the fact that the end-points for biochemical
complete regression and biochemical progression differ
significantly from study to study. There is general belief
that high-risk patients need postprostatectomy radio-
therapy, but recent analyses of a large body of clinical
data [13, 14] have shown no difference in 10-year survival
between postoperative RT and prostatectomy alone.
Pooling together the most reliable data, the dose-response
curve shows an "effect plateau" (Figure 1, curve B), similar
to that observed for squamous cell carcinomas of the
head and neck. However, the origin of the plateau for
each of them seems to be quite different. Possible
explanations for this are illustrated in Figure 2 (I and II).
Whereas for H & N cancers (Figure 1-(I)) accelerated
repopulation could be the major determinant of the
“effect plateau”, for adenocarcinoma of the prostate
(Figure 1-(II)), which is in general a very slowly proli-
ferating tumour, persistent hypoxia and a lesser average
response to 2 Gy fractions, may explain no gain above
74-76 Gy.
Figure 2. Theoretical and graphical illustration of two different mechanisms which likely lead to the effect plateau in conventional radiotherapy:
(I-a) – Dashed area represents TCP-dose relationship for tumours with 109-1010 equally radiosensitive tumour cells (D10=7 Gy) with no
repopulation. A shift of these curves to the region of lower doses (solid line -y) suggests that in fact epithelial cancers contains one or two logarithms
of cells more sensitive than the average. Flattening the upper part of the TCP curves in the region of higher doses is the result of decrease in
“effective dose” due to gradual increase of “wasted dose” compensated by repopulation. 
(I-b) – The longer OTT is the more dose is balanced by accelerated repopulation whole cell kill effect might be compensated by repopulation of
tumour cells surviving daily fraction doses (I-c) and the TCP-plateau reflects the cell surviving plateau. Therefore time is the major determinant,
although a subpopulation of radioresistant cells could contribute to a plateau.
(II-a) – TCP-plateau for prostate cancer may reflect on increasing size of initial hypoxic subpopulation because conventional 2 Gy fractions are not
effective enough to kill hypoxic cells, and/or pO2 gradually decreases (II-b). Time becomes unimportant and the size of dose per fraction and
intensity of its accumulation in consecutive weeks of treatment play the major role.
3
Figure 1. Dose-response for (A) head and neck cancer; (B) prostate
cancer; (C) IMRT. TCP curves have been estimated based on the
published clinical data and results [6, 8-11, 14, 17, 18, 20]. Solid and
dashed curves represent conventional techniques. The capital letters
refer to the results of trials of treatment of H&N cancer using
conventional (C), hyperfractionated (H) or accelerated –
hyperfractionated (AH) irradiation. Dotted curve for IMRT indirectly
drawn from the recently published data [11, 17, 20] shows steeper
slope than those for conventional RT and that by using IMRT the
plateau effect might be reduced.
Figure 2.II.Figure 2.I.
In summary, even after decades of evolution of
radiation therapy we still do not know how to optimize
treatment for the individual patient and only have
“averages” and ill-defined “probabilities” to guide treat-
ment prescription. The major problem is that patients
recruited into clinical trials are heterogeneous in their
radiation responses and their tumours have hetero-
geneous subpopulations and responses despite having
what appear, at first glance, to be uniform characteristics
on which they are randomized. Another uncertainty is
that the TNM or AJCC systems are useful for surgery
because they are relevant to removal of bulky tumours or
nodes, but is not so logical for radiotherapy in which the
only aim is to sterilize all cancer cells. In this sense it is
volume, not stage of disease which is relevant. Within
one stage there can be a ten-fold variation in tumour
volume. Finally, basic radiobiological guidelines concern-
ing average cell killing of “uniformly distributed” and
“equally radiosensitive tumour cells” arose from elegant
but idealistic in vitro experiments and seem to be of
uncertain validity. Radiobiological models for cell killing
fit experimental data but they have not been proven
“correct” for clinical data. Nowadays, therefore, we are
confronted with more dilemmas than dogmas.
Nolinearity and individual inhomogeneity
In 1981 Stewart pointed out that “Nature is relentlessly
nonlinear”. This raises questions about the salient aspects
of fundamental radiobiology, identification of the causal
roles in tumour response of the factors of time, total dose,
dose per fraction and of target volume and the validity of
current methods and techniques of irradiation. Real-time
image-guided radiotherapy needs urgent replacement of
model-driven methods by data-driven methods which
enable radiation oncologists and physicists to deal with
the tumours and their characteristics as they really are,
rather than as they can be simulated by models. For the
last few years this process is already in progress and it
has been quickened in 2001 by the 6th Conference on Dose,
Time and Fractionation Radiation Oncology in Madison,
USA.
It is no longer necessary to impose the assumption
(often incorrect) of a normal (Gaussian) distribution of
a set of clinical data in order to derive the p-values of
classical statistics. Nor, is it necessary to assume (almost
always incorrectly) that the patient's target volume is
a regular solid. Thus classical statistics providing estimates
of the significance of the probability of obtaining the
current set of data given the null hypothesis are replaced
by Bayesian statistics which provides estimates of the
probability of a hypothesis, or of a future observation,
given the current set of real-data. That eliminates ave-
rages, uniform cell density and equal radiosensitivity.
Consequently, radiation killing of a constant cell fraction
by consecutive and equal daily fractions should be
questioned and may be revised. The model concept of
equal cell killing per treatment day may or may not work
from tumour to tumour, and this could be supported by
the flattening of dose-response curves and the “effect
plateau” already derived from clinical data for many
tumours (Figure 1).
Studies on tumour cellularity strongly suggest that it
is far more diverse and heterogenous than we think.
Recently, Wilson from Gray Cancer Institute [15] pre-
sented a cellular model of the tumour with molecular
pathways of its growth (Figure 3) which is more complex
than in previously widely accepted radiobiological models.
It shows that the tumour is composed of heterogenous
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Figure 3. Scheme of cell subpopulations in the epithelial tumour with the key pathways
and genes involved in tumour growth, modified from Wilson [14]. Flash arrows to the
targets illustrate their relative radioresistance.
subpopulations of cells, whose fate may be natural (e.g.
exfoliation, apoptosis) or cytotoxic death from chemo-
therapy, or removal (surgical excision), but others may
persist in a viable state for long periods and could be
recruited back into the cell cycle. There are also subpo-
pulations of metastatic cells which may migrate out of
the tumour. Therefore, we are dealing in daily practice
with heterogenous individual tumours even if clinical
classification puts some of them into the same TNM
stage.
It is important to recognize gross tumour mass and
subclinical deposits of tumour cells. Available images
(CT, MRI, PET with image fusion) allow gross tumour
delineation with relatively high precision. The next
important step is to localize and measure the size and
density of tumour cell subpopulations of differing
radiosensitivities which have to be destroyed. Although
our skills in this field are improving, we are not able yet to
achieve this goal.
In 2000 Hellman and Heimann 16] proposed to
define breast cancer as a “spectrum of disease” instead of
the popular description as “systemic disease,” arguing
that such a definition covers all possible evolutions of
the disease; those which will never develop distant
metastases (DM), which already demonstrate DM at the
time of diagnosis, and those which will surely develop
DM sooner or later (from subclinical deposits already
present during the first admission or from locally
persistent primary or nodal failures). It is well docu-
mented that for node-negative (N0) cases long-term
survival after local therapy is about 80% and among T1-
T2N0 patients treated radically on an average 10-15%
will fail because of DM. Analyzing a database of 2136
N0 patients who underwent mastectomy only, in the same
centre, the authors found that evaluation of selected
molecular markers, i.e. MVC (microvessel count), E-
cadherin, nm23 and p53 allowed separation of N0 cases
with very low (close to zero) risk of DM from those with
high risk.
The group from Sloan Kettering Cancer Centre in
New York [17, 18] has used PET for imaging hypoxic cell
deposits within the prostate tumour target in order to
escalate and modulate dose distribution in these regions.
Furthermore, they found greater tumour cell density in
the apex and the lower posterior part of the prostate.
Van der Kogel from Cancer Institute in Nijmegen (The
Netherlands) developed assays for molecular mapping
of hypoxic cells in head and neck tumours. These
examples show that theoretical and practical changes
from uniformity to heterogeneity in radiotherapy are in
progress.
Non-uniformity and dose painting
For decades radiation oncologists have aimed for precise
and uniform dose distribution within the target volume
because through all these years till now the rule of
random cell killing of equally distributed and equally
radiosensitive tumour cells was widely accepted. Techno-
logical innovations such as high-tech linear accelerators
with portal vision, multileaf colimators, exact track
correcting for organ movements, 3D treatment planning
with CT and MRI images to construct Dose-Volume
Histograms (DVH) led to conformal (3D-CRT) non-
coplanar (3D-NRT), stereotactic (3D-SRT), dose intensity
modulated (IMRT), and recently 4D-Synergy (gating)
IMRT techniques. The advantage offered by 3(4)D-CRT
and IMRT over conventional RT is that conformally
tailored IMRT is individually capable of delivering
different doses to multiple target sites with extremely
high dose gradient between tumour and critical normal
tissues.
The DVH clearly illustrates the advantage of 3D-
CRT over conventional RT (Figure 4A – dashed vs.
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Figure 4. Examples of Dose-Volume Histograms (DVH) – with physical (A) and biological (B)
cold spots. Upper-right corner of DVH (A) should be of the major interest. Any shallowness of
this part may reflect physical cold spots. Optimal DVH with uniform dose distribution within the
target may cover up biological cols spot (B) caused by relatively resistant hypoxic cells which
would need an extra boost dose (tail on the DVH).
dotted line). The critical part of the DVH in predicting
tumour control probability is its upper-right corner. Sharp
bending of the DVH curve in this corner illustrates
uniform dose distribution within the tumour target. IMRT
can provide a more precise DVH than 3D-CRT (Figure
4A – solid vs. dashed line). However precise definition of
the visible tumour (GTV) then becomes critical. The
CTV is drawn subjectively based on the assumption of
local subclinical spread and no imaging methods can
improve its precision. In contrast, the PTV can probably
be shrunk by improving set-up accuracy.
Compared with conventional techniques and dose
fractionation (Figure 1A,B) IMRT allows to achieve
increased steepness of the TCP curve (Figure 1C). The
effect plateau may disappear due to increasing the dose
within a precisely defined target, and sparing of critical
organs enlarges the “safety window” (higher TCP with
lower risk of late side effects). Thus, higher therapeutic
benefit can be expected [17-20]. On the other hand, a high
dose gradient (and dose per fraction), within relatively
short distances increases the risk of geographical miss,
and pure physical DVH can be misleading. The rapid
change in dose per fraction, as well as in total dose
suggests that physical DVHs should be converted into
Biologically Normalized DVHs (BNDVH) reflecting, at
least, corrections for change in dose per fraction [19].
Because IMRT allows margins to be reduced, the
danger of edge misses enlarges (Figure 4A – dashed line).
Any cold spot within the edge of the tumour ruins the
potential benefit of higher doses for increasing of local
tumour control (TCP). A 50% dose deficit (dose gra-
dient) in only 1% of the volume reduces TCP to zero,
and a 25% dose deficit in 2% of the volume reduces TCP
from 90 % to less than 30%. Considering all the
advantages and risks of 3D-CRT and IMRT an important
question arises – do we really need dose distribution as
uniform as possible within heterogenous tumours?
For the last few years the complexity of the cellular
pattern of the tumour has become apparent (Figure 3).
Subpopulations of clonogenic (stem) cells, slow or fast
proliferating cells, recruited cells and hypoxic tumour
cells, as well as fibrotic, inflammatory, endotherial and
stromal cells representing various types of normal tissue
form a whole tumour. Tumour cell pattern is further
complicated by variations in cell density. In fact, neither
normal cells nor some of the cancer cells (which are still
alive but never will proliferate) are the real targets for
radiation. Modern radiotherapy should not be considered
as “tumour focused” but rather as “cancer cells targeted”.
Subpopulations of “target cells” are not uniformly distri-
buted within the tumour, and they may differ by loca-
lization, size, cell density, proliferative activity and
radiosensitivity. Therefore, different doses with probably
different fractionation are likely required to kill all of
these tumour cells which are viable and proliferative. It
leads to the conclusion that uniformity should no longer
be considered as the primary attribute for specifying the
dose within the targeted tumour, and “cancer cell targeted
radiotherapy” needs heterogenous dose distribution with
deliberately and precisely designed “biological hot spots”.
This is the idea of so-called “dose painting”. Hot spots in
the tumour are not dangerous, unless they are also in the
wrong places (normal structure). It seems, that dose
painting is not a science fiction scenario but is a real-
time radiotherapy for biologically and clinically hetero-
genous human tumours.
To discuss the need of dose painting let's consider an
example of an individual epithelial tumour with two
subvolumes of 108 and 109 cells each, being of the same
size, equally proliferative, radiosensitive and well
oxygenated, and cell density is the only difference.
Assuming D10 of 7 Gy*, the total dose (TD) of 63 Gy (9 x
7 Gy) will reduce the 108 subpopulation to an average
0.1 surviving cell which gives a TCP of 90%. If such TD
would be uniformly distributed also in the second
subpopulation, 1 cell will survive on average, and give
TCP of 37% (e-1). Therefore, for TD of 63 Gy overall
TCP will decrease from the expected 90% to about 33%
because the same dose is uniformly distributed within
two subpopulations containing different numbers of
cancer cells. To keep TCP around 90%, the 109 popu-
lation should receive 70 Gy. The increase or decrease in
TCP from changing the dose within subvolumes with
inhomogenous cell densities can be estimated (Figure 5).
Figure 5 shows that the benefit from overdosed sub-
volumes increases as control rates with standard uniform
treatment decrease.
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* D10 is handy parameter because it is the dose that reduces survival
by one common logarithm. If the tumour has 108 cells then 9 x D10
corresponds with the TCP = 90% [TCP = e-x, where “x” is an
average number of cells survived; after 9 x D10 – x will be 0.1 and 
e-0.1 = 0.9 (90%)]. D10 is about 2.3 x effD0 which for squamous
cancer cells and 2 Gy fractions is about 3.0 Gy, therefore D10 = 7 Gy.
Figure 5. Predicted increase in TCP due to nonuniform dose
distribution within the target (according to Withers et Lee, 20), which
yields dose greater by 1 x the D10 value. The greatest benefit can be
expected when the TCP for prescribed dose is relatively low and when
the tumour subvolume receives a higher “boost dose”.
Making the example above more complex let's
assume that in the 109 subpopulation one logarithm of
cells would be hypoxic. This will drop the TCP down to
zero for TD of 63 Gy. To keep the TCP still at the same
level of 90%, as for an 108 subpopulation, D10 should
increase to 17.3 Gy assuming OER of 2.5**. In such
a situation, TD covering the 109 cell tumour should
increase from 63 Gy to 80.3 Gy but the size of the last 2-3
fractions should be 7.5 Gy. It would be even more
effective if 17.5 Gy will be delivered as a single dose (high
dose rate brachytherapy boost). Therefore this example
also illustrates the need of variation in dose fractionation
given as a boost. If 17.3 Gy would be given in 2 Gy
fractions the boost may not work, whereas hypo-
fractionated or as a single dose it will.
In clinical practice, predicting TCP is potentially
complicated by many causes of heterogeneity in radiation
response, such as the presence of subpopulations of rapid
proliferating cells and/or intrinsically resistant cells but the
common conclusion is that various regions of the tumour
need, with no doubt, different total doses of radiation
and likely different fractionation schedules. Therefore it
seems unrealistic that a single cell survival curve (SF)
could represent the response of human tumours to
radiation. Rather, a series of SF curves would be more
reliable (Figure 6A). Consequently the standard aim of
a DVH with homogeneous dose distribution within the
target and with its sharp upper-right bend would not be
optimal, and the tail, representing a boost dose to
biological hot spots (Figure 6B) would better reflect the
tail in the survival curve (Figure 4A). Fowler pointed out
that not 95% of target must receive at least 100% dose,
but that one has to specify a definite minimum target
dose, and the target effective uniform dose (EUD) should
exceed the prescribed tumour dose [21].
As mentioned earlier, pure physical DVH (especially
for IMRT) might be misleading because of physical cold
spots and/or a large dose gradient within a relatively short
distance. But even it these factors are accounted for and
corrected by BNDVH, uncertainty does not disappear
and the risk of biological cold spots remains if subvolumes
of hypoxic, resistant, or fast proliferating cells exist in the
tumour (Figure 4B). In such a situation it seems that
dose painting is the only solution, if it can be accurately
targeted.
Increasing application of 3D-CRT and IMRT in daily
practice needs precise definition of “dose escalation” and
“dose intensity” because they are often misinterpreted
and interchangeably missused one for another. Dose
escalation (DE) simply means the increase in total dose. It
may or may not increase biological efficacy (higher TCP).
If extra dose is delivered to an epithelial tumour
as a fractionated boost with extension of OTT it could
be completely balanced by accelerated repopulation,
and such dose will be “wasted” but not “escalated” in
a biological sense. By contrast, short HDR-brachytherapy
boost given in the last day of fractionated radiotherapy is
effective escalation of dose.
Dose intensity (DI) quantitatively describes how
intensively the units of dose are accumulated during
treatment time, and it is closely related to its biological
efficacy. It can be expressed by the number of Gy given
per one day of treatment or by the ratio of effective
treatment days and overall treatment time. For example,
for conventional 66 Gy in 45 days, the DI is 1.47 Gy/day
whereas for 66 Gy in 35 days (DAHANCA 7 trial) the DI
increases to 1.71 Gy/day. Using the time factor, 5-day
a week radiotherapy describes the DI of 0.71 „effective
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** For OER 2.5, effD0hypoxic = 2.5 x effD0oxic = 2.5 x 3 Gy = 7.5 Gy
and then D10 = 2.3 x 7.5 Gy = 17.3 Gy.
Figure 6. Multicomponent cell survival curve reflecting response of different cell-
subvolumes in the tumour. This would support the use of a heterogenous dose distribution
in the target volume which is graphically illustrated by the “boost tail” in the DVH.
treatment time” (5/7), which increases to 0.86 for 6-day
a week treatment [22]. The DI estimates should be
interpreted carefully because 10-12 Gy given in the first
week of RT is not biologically equivalent to 10-12 Gy
given in week 6 of RT. It means that the DI is biologically
higher during the first 2-3 weeks of treatment and
significantly decreases with extension of overall treatment
time at least for epithelial tumours. It seems likely that
beyond week 6 of RT the DI may drop down to zero and
result in the “effect plateau”, unless accumulated dose
per week is higher than 14 Gy.
Is there evidence of nonuniformity and the need of
dose painting
Heimann and Hellman [16] documented that by using
a combination of molecular markers for metastatic
potential (MVC, nm23, E-cadherin, p53) it is possible to
select a subgroup of patients with T1-2N0 breast cancer
with almost no risk of distant metastases (low MVC and
p53, and high E-cadherin and nm23) for which 20-year
disease-free survival is close to 100%.
In DAHANCA-7 trial [22] 6-day per week RT for
a clinically homogenous group of patients with sup-
raglottic cancer has produced an average benefit of LRC
of 9%, but in the selected subgroup of well differentiated
cancers this benefit increased to 15%, and, within this
subgroup, it further increased for a series of patients with
high expression of EGFR.
The most fascinating current information is that
prostate cancer appears to have an unusual radiobiology
and it may likely respond to change in dose-fractionation
similarly to late-responding tissue [23] because of a very
low α/β ratio of 1.49 Gy (95% CI of 1.35-1.63 Gy). This
offers a unique opportunity for hypofractionated radical
RT to improve therapeutic ratio. Among a few schedules
designed by Ritter and Fowler [23], 10 fractions of 4.68
Gy seems to be plausible (Figure 7). The low α/β ratio
probably reflects the presence of inherently resistant
and/or hypoxic subvolumes in the prostate cancer.
Zelefsky and Ling [17, 18] have shown the potential of
PET images to provide both topographical and biological
data. Biological images broadly include those in the
metabolic, biochemical and functional categories. The
increased enthusiasm for PET is in part due to the
availability of different tracers (Table I). These advances
make prostate cancer an interesting candidate for IMRT
dose escalation and painting. Using dose painting, high
doses can be restricted to the anterior part of the rectal
wall only and the benefit has been validated by recent
results showing a significant decrease in late complication
rate [17]. Therefore, it may suggest that conventional and
prolonged fractionation may neither be necessary nor
optimal for prostate cancer. Martinez' group from the
Beaumont Centre indicates that 3D-real time conformal
HDR brachytherapy can eliminate many of the critical
problems that have hampered dose escalation with 3D-
CRT (24).
There is no doubt that dose painting needs precise
quantitative imaging of tumour cell inhomogeneity.
Recent advances in nuclear medicine are dedicated to
the pursuit of molecular imaging with a potential
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Table I. Tumour biology images (cell subvolume characteristics and functions)
Tumour characteristics Method Tracer End-point
and/or functions
tumour blood perfussion, diffussion, MRI/1H-MRS Gd-DTPA T1 signals ↑
blood-brain barrier permeability (gadolinium 
diethylenetria-minepentaacetic acid
blood-oxygenation MRI/1H-MRS deoxygenated Hb Oxy – Hb ↑
level-dependent (BOLD) T2 signals ↑
malignant/benign tumour (mainly prostate), MRI/1H-MRS Choline/citrate Ch/c ratio↑
tumour burden/cell density
tumour oxygenation MRI/1H-MRS Lactate Lact. ↑ - hypoxia
FDG detection, stage, recurrence
tumour oxygenation, growth PET 124I/UdR proliferated subpopulation
tumour malignancy PET 11C – Misonidazole hypoxic cell-subvolume
tumour growth PET 11C – Methionine proliferative activity
tumour apoptosis PET 99Tc – Annexin V cell death imaging
Figure 7. Dose per fraction escalation schedules (from conventional
to hypofractionated) predicting tumour control benefit for prostate
cancer for constant late normal tissue toxicity (from Ritter and Fowler,
23).
resolving power on the order of 20 µm (25). Studies with
radioiodinated phospholipid ether (PLE) which is
selectively trapped in the membrane of tumour cells,
suggest that it could be a potential tumour-selective
imaging agent [26]. Clinical studies indicate that the use
of inhibitors of the EGFR and the VEGFR may enhance
intrinsic radiosensitivity and thereby increase the ulti-
mate tumour response, reducing the need for dose
escalation. Intensive studies on molecular mapping
together with molecular modifiers and IMRT-dose
painting open a new era of “nonuniform tumour cell-
targeted radiotherapy”.
Criticisms and perspectives
Molecular mapping and dose painting becomes a realistic
scenario for the near future in radiotherapy. We learned
that the human genome includes approximately 30 000 to
35 000 genes and the growth of various human tumours is
initiated and regulated by only about 1000 genes, but on
the other hand, by as many as 1000 genes. To learn about
all their functions and interactions needs time but it may
progressively change not only oncology but likely all
medical practice. What we know now is that each
individual tumour has its own characteristic cell-pattern
which needs nonuniform dose-painting or modification or
radioresistance (e.g. by eliminating the effect of hypoxia)
which should also include surgery and chemotherapy in
order to destroy cellular reproductive integrity of all
tumour clonogens. We are not able yet to identify
accurately areas of increased density, proliferative activity,
resistance and hypoxia. Therefore localized dose esca-
lation has an inherent potential for geographical errors.
To achieve a benefit hypoxic subvolumes require a sig-
nificant increase in dose but hypoxia might be distributed
throughout the whole tumour instead of being in one or
two localized areas and may change from day to day.
Therefore to selectively target foci of radioresistance
needs precise and repeated functional imaging.
One can be sceptical but none can ignore the
perspectives. We have to be prepared for collection
of a large number of genetic and molecular data in
parallel with clinical data, treatment parameters and
results of treatment. Therefore the latter ones should
be as accurate as possible. It seems likely that the rules
of randomization and clinical trials may change be-
cause we will be looking for homonogeous groups with
respect to both clinical and molecular parameters re-
levant to radiation responsiveness. Methods of ana-
lysis may also change into comparison of two tumours
with identical cell characteristics, one cured and another
one failed, to establish their genetic and molecular
differences in order to recognize which characteristics
are responsible for the failure. Notwithstanding all of
these uncertainties and criticism the conclusion seems
that openess,mutual contacts and, collaboration and
intensive exchange of precise information are basic and
urgent fundaments for effective progress, not only in
radiotherapy. In fact it might be the beginning of so-
called global oncology.
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